Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine

(Landes Bioscience) A long-term follow-up study shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papillomavirus vaccine Cervarix. Women vaccinated with the vaccine were followed for more than nine years, and vaccine efficacy against incident infection was 100 percent. This is the longest follow-up report for a licensed human papillomavirus vaccine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news